Age Ayurveda Nighantu Ayurvedic practitioner? List or verify your practice

Shankhpushpi

Convolvulus pluricaulis

Shankhpushpi (Convolvulus pluricaulis) is a plant drug, from the Convolvulaceae family. Monographed in the Ayurvedic Pharmacopoeia of India (API) as Shankhpushpi (whole plant). AChE inhibition: Significantly inhibits acetylcholinesterase activity in cortex and hippocampus, increasing acetylcholine retention in synapses.

Key facts
Botanical nameConvolvulus pluricaulis
Identity sourceAyurvedic Pharmacopoeia of India, Part I, Vol. II: SANKHAPUSPI (Whole Plant)
Also calledConvolvulus prostratus (nomenclatural synonym)
Clitoria ternatea (named in the Pharmacopoeia as also used)
Evolvulus alsinoides (named in the Pharmacopoeia as also used)
Currently accepted nameConvolvulus prostratus Forssk., the name above is treated as a synonym by GBIF; both are in use
FamilyConvolvulaceae · other entries in this family
OrderSolanales
Pharmacopoeia statusMonographed in the Ayurvedic Pharmacopoeia of India (API) as Shankhpushpi (whole plant). API recommends the plant for epilepsy. Documented in Indian Pharmacopoeia since the 1996 edition with quality control standards. First referenced in Charaka Samhita (c. 1st-2nd century CE) as a brain tonic for intellect and nervous system. No standalone WHO monograph identified.
Taxon identifiersGBIF 3679942 · Wikidata Q5166609

The evidence at a glance

12papers on this site for this drug, published 2006 to 2026, every one with a DOI.

  • 1Systematic reviews and meta-analyses
  • 6Other clinical studies and reviews
  • 5Laboratory and animal studies

A count is not a conclusion and a tier is a study design, not a verdict. Each paper is listed with what it measured on the page below. See the research index for how papers are tiered.

Names and identification

LanguageName
EnglishShankhpushpi

How does it work?

  • AChE inhibition: Significantly inhibits acetylcholinesterase activity in cortex and hippocampus, increasing acetylcholine retention in synapses.
  • Multi-target neuroprotection: Active compounds interact with PTGS1/2, NOS3, INSR, HMOX1, ACHE, PPARG, MAOA, and MAOB molecular targets.
  • PPARgamma activation: 4-hydroxycinnamic acid and scopoletin activate PPARgamma signaling to ameliorate cognitive deficits.
  • Tau protein modulation: Ameliorates hMAPtau-induced neurotoxicity, extending lifespan in Alzheimer’s Drosophila models.
  • Antioxidant activity: Enhances antioxidant enzyme activities, reducing oxidative stress in neural tissue.
  • Synaptic plasticity modulation: Modulates synaptic plasticity in hippocampal neurons.
  • Dual mechanism: Exerts nootropic effects through combined anti-AChE and antioxidant action.
  • Key active constituents: Scopoletin, quercetin, 4-hydroxycinnamic acid, ayapanin, convolamine, and kaempferol.

What do recent studies show?

Only studies that could be traced to a published paper are listed here. An absence here means we could not identify the source, not that no work exists.

Recent safety updates

  • LD50 determined at 1250 mg/kg (range 1000-1500 mg/kg) for whole extract, indicating a relatively high safety margin at therapeutic doses.
  • Critical drug interaction: Reduces antiepileptic activity of phenytoin and lowers plasma phenytoin levels. Multiple-dose administration significantly impairs phenytoin efficacy.
  • May interact with antidepressants, antipsychotics, and other neurotransmitter-affecting medications.
  • Potential interaction with blood pressure medications due to mild hypotensive effect.
  • Possible interaction with sedatives and CNS depressants due to sedative-hypnotic properties.
  • Side effects uncommon; mild nausea possible due to bitter taste.
  • Cross-allergenicity possible in individuals allergic to Convolvulaceae family plants (e.g., sweet potato).
  • People with low blood pressure should use with caution; consult physician before use during pregnancy.

Dosage forms and preparation

Dosage Forms: Syrup, Churna (powder), Capsule, Tablet, Kwatha (decoction), Swarasa (fresh juice), Ghana vati, Drops (for children)

Standard Dosage: 3-6 g powder per day; 10-20 mL syrup twice daily; 500-1000 mg extract capsule twice daily; 5-10 mL swarasa twice daily; children: 2.5-5 mL syrup twice daily

Optimal Timing: Morning and evening for cognitive benefits; traditionally taken with ghee or milk. Before exams/study sessions for students (traditional use).

Storage: Syrup: below 25 deg C, refrigerate after opening. Capsules and churna: airtight containers below 25 deg C, protected from light and moisture.

Marker Compounds: Shankhapushpine, Scopoletin, Kaempferol, Convolvuline, Beta-sitosterol, Microphyllol, 20-Oxodotriacontanol

Synergistic Combinations

Published research

Literature indexed in PubMed that concerns this subject, grouped by study type. A paper appearing here is a record of what has been published, not evidence that the subject works, and laboratory or animal results do not transfer to people. Study titles link to PubMed so you can read the source rather than take our word.

Systematic reviews and meta-analyses1

  1. Sharma R, Singla RK, Banerjee S and others. 2022. Role of Shankhpushpi (Convolvulus pluricaulis) in neurological disorders: An umbrella review covering evidence from ethnopharmacology to clinical studiesNeuroscience and biobehavioral reviews. PMID 35878793 · doi:10.1016/j.neubiorev.2022.104795

Other clinical studies and reviews6

  1. Firdaus A, Yunus MH, Izhar SK and others. 2025. Medicinal Plants in the Treatment of Respiratory Diseases and their Future AspectsRecent patents on biotechnology. PMID 38275072 · doi:10.2174/0118722083278561231212072408
  2. Gayathri S, Raghu CH, Fayaz SM. 2022. Phytotherapeutics against Alzheimer's Disease: Mechanism, Molecular Targets and Challenges for Drug DevelopmentCNS & neurological disorders drug targets. PMID 34544351 · doi:10.2174/1871527320666210920120612
  3. Garg G, Patil A, Singh J and others. 2018. Pharmacological evaluation of Convolvulus pluricaulis as hypolipidaemic agent in Triton WR-1339-induced hyperlipidaemia in ratsThe Journal of pharmacy and pharmacology. PMID 30182365 · doi:10.1111/jphp.13004
  4. Agarwa P, Sharma B, Fatima A and others. 2014. An update on Ayurvedic herb Convolvulus pluricaulis ChoisyAsian Pacific journal of tropical biomedicine. PMID 25182446 · doi:10.1016/S2221-1691(14)60240-9
  5. Singh RH, Narsimhamurthy K, Singh G. 2008. Neuronutrient impact of Ayurvedic Rasayana therapy in brain agingBiogerontology. PMID 18931935 · doi:10.1007/s10522-008-9185-z
  6. Kumar V. 2006. Potential medicinal plants for CNS disorders: an overviewPhytotherapy research : PTR. PMID 16909441 · doi:10.1002/ptr.1970

Reviewed by Dr. Awadesh Pratap Singh, BAMS, on 11 October 2026. What that review covered.

Available from Age Ayurveda

This encyclopedia is published by Age Ayurveda. The products below are ours, and are listed here because they contain or use what this page describes.

Consult a qualified vaidya before acting on anything here. Ayurvedic practice is prescribed to a person, not to a condition: the same dravya is given, withheld or substituted depending on your constitution, your agni, the season and what else you are already taking. A page cannot know any of that. Self-prescribing from a reference is how the wrong preparation, the wrong dose or the wrong anupana gets used.

Educational reference only. Nothing on this page is medical advice, a diagnosis, or a recommendation to take anything. Traditional uses and research findings are reported as published, not as claims about what any product does. If you take prescribed medication, raise any interaction with the prescriber rather than acting on a page. See our editorial standards.